Dr. Galia Temtsin Krayz

Dr. Galia Temtsin Krayz is the Chief Executive Officer and Head of the Research and Development (R&D) department at the company. With a remarkable career spanning over two decades in the Life Science and Pharma industries, Dr. Temtsin Krayz is a highly respected and recognized expert in these fields.

Throughout her career, Dr. Temtsin Krayz has made significant contributions to the industry as an inventor of several proprietary technologies. These include SolumerTM-oral, Omexa-transmucosal sublingual, and Nasax-intranasal. These innovative technologies have the potential to revolutionize drug delivery systems and improve patient outcomes.

Before joining the Formulex, Dr. Temtsin Krayz worked at Solubest Ltd. for 15 years, where she progressively advanced from a researcher to the CEO position. Her extensive experience in various roles within the company has provided her with invaluable insights into the industry.

Prior to Solubest, Dr. Temtsin Krayz worked at Perrigo (Chemagis, Israel) as a project manager, further enhancing her expertise in the pharmaceutical field.

As the CEO and Head of R&D, Dr. Temtsin Krayz holds key responsibilities in business development and oversees the development of various drug delivery systems, including oral, sublingual, topical, nasal, and injectable formulations. She is also involved in the development of combination products with medical devices.

Dr. Temtsin Krayz’s educational background includes a Bachelor of Arts degree in chemical education with top honors from Moscow Teachers Institute, Russia. She further pursued her studies and obtained a Master of Science degree in chemistry from Ben-Gurion University of the Negev, Beer-Sheva, Israel. She completed her Ph.D. in chemistry, specializing in organic chemistry and nanomaterials, from the same institution. Additionally, she holds an MBA in BioMed from The College of Management, Academic Studies, Rishon Le Zion, Israel. Her extensive academic and industrial experience in organic synthesis, process development of active pharmaceutical ingredients (APIs), and drug delivery systems further strengthens her expertise.

Dr. Temtsin Krayz’s leadership and expertise drive the company’s R&D efforts, ensuring the development of innovative drug delivery solutions and contributing to the growth and success of the organization in the life science and pharmaceutical industries.